Message :
Required fields
Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares HIGHLANDS RANCH, Colo., May 11, 2021 - Vivos Therapeutics, Inc. (Nasdaq: VVOS) ( Vivos ), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters option to purchase additional shares of common stock, at a public offering price of $6.00 per share.
Vivos Therapeutics Announces Pricing of $24 Million Follow-On Offering
HIGHLANDS RANCH, Colo., May 06, 2021 (GLOBE NEWSWIRE) Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.
The aggregate gross proceeds to Vivos from the public offering are expected to be $24 million prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Vivos has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of common stock to cover over-allotments, if any.
(VVOS) - Vivos Therapeutics Leads the Battle Against Obstructive Sleep Apnea (OSA) benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
IPO Alert: Vivos Therapeutics
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Highlands Ranch, Colorado-based Vivos Therapeutics is scheduled to go public on the Nasdaq Global Select Market under the symbol VVOS on December 11, 2020.
Vivos Therapeutics, founded in 2007, is a revenue-stage medical technology company developing devices for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA).
The company has offered to sell 3.5 million shares of common stock in the offering at $6 per share, and the underwriters have an option for 45 days to buy up to 525 thousand additional shares. The company expects gross proceeds from the offering to be $21 million.
Underwriters of the IPO: